Open Surgery Instruments – Market Insights – United States

The US open surgery instrument market is projected to grow gradually through 2034, supported by the continued uptake of advanced, premium-priced technologies such as direct energy and closure devices. However, this growth will be tempered by the ongoing shift toward MIS techniques—including both laparoscopic and robotic-assisted approaches—which continue to displace traditional open procedures across many specialties. While robotic-assisted surgery is gaining traction, the lack of incremental reimbursement for these procedures is expected to moderate the pace of adoption. Additionally, the rising use of GLP-1 receptor agonists, which has reduced the demand for bariatric surgeries, will further constrain growth in certain open surgery segments.

This Medtech 360 Report provides comprehensive data and analysis on the state of the US open surgery instrument market from 2019 through 2034.

The continued rise of MIS, particularly robotic-assisted techniques, is contributing to a steady decline in open surgery procedure volumes.

Which procedures still rely heavily on open techniques, and which have seen the greatest shift toward MIS?

As robotic surgery expands, which open procedures are maintaining growth, and which are approaching saturation?

Between open and laparoscopic approaches, which is more significantly impacted by the rise of robotics?

Emerging technologies and innovative products will grow in popularity at the expense of competing treatment options.

What are the latest innovations shaping the open surgery instrument market?

How might these advancements influence adoption?

What role does clinical evidence play in driving uptake of new technologies?

GLP-1 receptor agonists have been experiencing a meteoric rise in adoption among the US patient population in recent years.

Considering the emerging pharmacological therapies in the pipeline, what is the outlook for bariatric surgery procedures?

How has the rise in GLP-1 receptor agonist prescriptions affected the laparoscopic device market?

Will the laparoscopic device market recover from the increasing use of GLP-1 receptor agonists?

Significant changes were made to CPT reimbursement for anterior abdominal hernia repair.

What were the changes introduced by recent CMS coding updates for anterior abdominal hernia repair procedures?

What are the implications of altered CPT reimbursement on hernia repair procedure volumes?